Zimmer Biomet Holdings (ZBH) Tops Q3 EPS by 2c, Slight Miss on Revenues

Zimmer Biomet Holdings (NYSE: ZBH) reported Q3 EPS of $1.63, $0.02 better than the analyst estimate of $1.61. Revenue for the quarter came in at $1.84 billion versus the consensus estimate of $1.84 billion.

"We are pleased with our third quarter accomplishments, which reflect our sustained progress in a number of areas. Although our sales results clearly benefited from less challenging sales comparisons, as well as the timing of certain tenders and capital sales, our organic growth continued to signal that we are turning the business around consistent with our expectations," said Bryan Hanson, President and CEO of Zimmer Biomet. "Looking to the balance of the year, we will continue to focus on priorities to improve the consistency of our results and drive sustained value creation. These include important new innovations that are expanding our comprehensive portfolio, advancing standards of care and creating new opportunities for our salesforce to deliver growth."

For earnings history and earnings-related data on Zimmer Biomet Holdings (ZBH) click here.

You May Also Be Interested In

• Zimmer Biomet to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
• Petco Health and Wellness (WOOF) Misses Q1 EPS by 6c
• Morgan Stanley lifts MU and SNDK targets, sees 2-3 years of tight memory supply